新型碳青霉烯类联合方案在多药耐药革兰阴性菌感染治疗中的作用
综述总结碳青霉烯/β-内酰胺酶抑制剂(BLI)联合方案(美罗培南/伐硼巴坦、亚胺培南/西司他丁/瑞来巴坦、美罗培南/纳库巴坦)的临床前与临床证据,聚焦美罗培南/伐硼巴坦。随机试验显示其治疗复杂性尿路感染非劣于哌拉西林/他唑巴坦,治疗严重CRE感染优于最佳可用治疗,且耐受性良好、毒性低于既往标准联合方案。
要点
- 三种BLI对肺炎克雷伯菌碳青霉烯酶及其他A类碳青霉烯酶均有体内活性。
- 美罗培南/伐硼巴坦对CRE有显著体内外活性,临床相关剂量下体外耐药潜力低。
- 随机试验中美罗培南/伐硼巴坦治疗复杂性尿路感染非劣于哌拉西林/他唑巴坦。
核心结论
- 碳青霉烯/BLI联合方案是多药耐药革兰阴性菌感染患者的重要治疗策略。
研究设计与样本
- 综述总结碳青霉烯/BLI联合方案的临床前证据及多药耐药革兰阴性菌感染的临床证据,重点为美罗培南/伐硼巴坦。
主要发现
- 三种BLI对肺炎克雷伯菌碳青霉烯酶及其他A类碳青霉烯酶均有体内活性。
- 美罗培南/伐硼巴坦对CRE有显著体内外活性,临床相关剂量下体外耐药潜力低。
- 随机试验中,美罗培南/伐硼巴坦治疗复杂性尿路感染非劣于哌拉西林/他唑巴坦。
- 随机试验中,美罗培南/伐硼巴坦治疗严重CRE感染优于最佳可用治疗。
- 美罗培南/伐硼巴坦耐受性良好,基于临床经验其毒性低于既往标准联合方案。
关键数值与推荐
- 2019年美罗培南/伐硼巴坦因对优先1级耐药病原体的活性被列入WHO基本药物清单。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multi-drug resistant (MDR) Gram-negative bacteria represent a growing threat, with an increasing prevalence of carbapenem-resistant Enterobacterales (CRE) infections, for which treatment options are limited. New treatment combinations composed of a β-lactam antibiotic plus a potent β-lactamase inhibitor (BLI) with anti-carbapenemase activity have been developed, including two carbapenem/BLI combinations that are commercially available-meropenem/vaborbactam (Vabomere® in the US, Vaborem® in Europe; Melinta Therapeutics) and imipenem/cilastatin/relebactam (Recarbrio®; Merck Sharp & Dohme), plus one other (meropenem/nacubactam) in early clinical development. This review provides a summary of the preclinical evidence supporting the use of carbapenem/BLI combinations and presents the clinical evidence across a range of MDR Gram-negative infections, with a focus on the use of meropenem/vaborbactam. All three BLIs have shown in vivo activity against Klebsiella pneumoniae carbapenemase and other class A carbapenemases. In 2019, meropenem/vaborbactam was listed in the WHO's list of essential medicines, because of its activity against priority 1 antibiotic-resistant pathogens. Meropenem/vaborbactam has considerable in vitro and in vivo activity against CRE, and in vitro evidence showing a low potential for resistance at clinically relevant doses. In randomized trials, meropenem/vaborbactam was non-inferior to piperacillin/tazobactam in patients with complicated urinary tract infection and more effective than the best-available treatment in patients with serious CRE infections. Meropenem/vaborbactam is well tolerated and, based on clinical experience, demonstrated lower toxicity compared with the combination regimens that have previously been the standard of care. In conclusion, carbapenem/BLI combinations represent an important therapeutic strategy in patients with MDR Gram-negative infections.
引用
- Bouza E. The role of new carbapenem combinations in the treatment of multidrug-resistant Gram-negative infections. J Antimicrob Chemother. 2021. PMID: 34849998. doi:10.1093/jac/dkab353
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。